Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00134498 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides
A Phase 3 study of Hypertriglyceridemia and Hyperlipoproteinemia Type IV, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 160
- Enrollment target
- 20
- Study locations
NCT00134498: Completed Phase 3 study of Hypertriglyceridemia and Hyperlipoproteinemia Type IV, sponsored by Pfizer.
NCT00134498 is a Phase 3 study of Hypertriglyceridemia and Hyperlipoproteinemia Type IV that has completed, run by Pfizer. The registered enrollment target is 160 participants, roughly in line with the 170-participant average among 25 other Hypertriglyceridemia trials with a reported enrollment target. The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00134498, a Phase 3 study of Hypertriglyceridemia and Hyperlipoproteinemia Type IV, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 160 participants
- Enrollment target
- 20
- Study locations
Study Summary
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To assess the safety and efficacy of the fixed combination torcetrapib/atorvastatin in subjects with Fredrickson Type IV Hypertriglyceridemia.
Conditions Studied
Interventions
- DRUG atorvastatin
- DRUG torcetrapib/atorvastatin
Study Locations (20)
California
- Pfizer Investigational Site - Anaheim
- Pfizer Investigational Site - Huntington Beach
- Pfizer Investigational Site - Los Angeles
- Pfizer Investigational Site - Orange
- Pfizer Investigational Site - Orangevale
- Pfizer Investigational Site - Pacific Palisades
- Pfizer Investigational Site - Studio City
- Pfizer Investigational Site - Tustin
- Pfizer Investigational Site - Walnut Creek
Florida
- Pfizer Investigational Site - Hollywood
- Pfizer Investigational Site - Longwood
- Pfizer Investigational Site - West Palm Beach
Connecticut
- Pfizer Investigational Site - Farmington
District of Columbia
- Pfizer Investigational Site - Washington D.C.
Hawaii
- Pfizer Investigational Site - Tripler AMC
Illinois
- Pfizer Investigational Site - Chicago
Indiana
- Pfizer Investigational Site - Indianapolis
Kansas
- Pfizer Investigational Site - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2005-02 |
| Est. Completion | 2006-11 |
| Phase | Phase 3 |
What the finished NCT00134498 record still lists
NCT00134498 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 170-participant average among 25 other Hypertriglyceridemia trials with a reported enrollment target.
The record links to 2 conditions, with Hypertriglyceridemia appearing as the primary indexed condition, and to 2 interventions - of which atorvastatin is the first listed.
NCT00134498 names 20 study sites across 10 states, led by California, Florida, Connecticut.
Frequently Asked Questions
What is clinical trial NCT00134498 about?
NCT00134498 is a clinical study titled "A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides". The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To assess the safety and efficacy of the fixed combination torcetrapib/atorvastatin in subjects with Fredrickson Type IV Hypertriglyceridemia.
What is the current status of trial NCT00134498?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 160 participants. The study started on 2005-02. Estimated completion is 2006-11.
What conditions does trial NCT00134498 study?
This clinical trial studies the following conditions: Hypertriglyceridemia, Hyperlipoproteinemia Type IV.
What interventions are being tested in trial NCT00134498?
The interventions under investigation include: atorvastatin (DRUG), torcetrapib/atorvastatin (DRUG).
Who is sponsoring clinical trial NCT00134498?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00134498 being conducted?
This trial has 20 study locations across California, Connecticut, District of Columbia, Florida, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertriglyceridemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00134498's enrollment target sits among peer trials
160 5th of 25 higher than 21 of 25 other Hypertriglyceridemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertriglyceridemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
RECRUITING · Phase 3
-
Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
ACTIVE NOT RECRUITING · Phase 3
-
Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy
COMPLETED · Phase 3
-
[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL
COMPLETED · Phase 3
-
A Mechanistic Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol
RECRUITING · Phase 2
-
Differential Thrombogenesis by EPA and DHA Mediated by HDL
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia